Juan Sanchez | VP, Corporate Communications and IR |
Sharon Mates | Chairman and CEO |
Larry Hineline | VP and CFO |
Andrew Satlin | EVP and CMO |
Kimberly Vanover | SVP, Clinical Development |
Brian Abrahams | RBC Capital Markets |
Jessica Fye | J.P. Morgan |
Ritu Baral | Cowen & Company |
Charles Duncan | Piper Jaffray |
Paul Matteis | Leerink Partners |
Sumant Kulkarni | Canaccord Genuity |
Bill Tanner | Cantor Fitzgerald |
Bert Hazlett | BTIG |
Matthew Kaplan | Ladenburg Thalmann & Co. Inc. |
Roy Buchanan | JMP Securities |
Good morning ladies and gentlemen and welcome to the Intra-Cellular Therapies' Fourth Quarter and Full Year ended December 31st, 2017 Financial Results Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will follow at that time. [Operator Instructions] And as a reminder, today's conference call is being recorded. I'd now like to turn the conference over to your host, Dr.